...
首页> 外文期刊>Rheumatology >Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
【24h】

Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.

机译:慢性免疫介导的患者结核病风险,慢性免疫介导的生物学和TOFACITINIB治疗:随机对照试验和长期扩展研究进行了系统审查和荟萃分析。

获取原文
获取原文并翻译 | 示例
           

摘要

RCTs are not sensitive enough to assess the risk of reactivation of latent TB infection (LTBI). Disease, treatment and background TB rate are associated with different frequencies of active TB. The benefit/risk balance of preventing reactivation of LTBI in different backgrounds should be considered in clinical practice.
机译:RCTS不足以评估潜伏结核病感染(LTBI)的重新激活的风险。 疾病,治疗和背景TB速率与不同的活性TB频率相关。 在临床实践中应考虑预防不同背景下LTBI重新激活的效益/风险平衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号